...
首页> 外文期刊>International journal of colorectal disease. >Tumor response to neoadjuvant chemoradiation in rectal cancer: predictor for surgical morbidity?
【24h】

Tumor response to neoadjuvant chemoradiation in rectal cancer: predictor for surgical morbidity?

机译:直肠癌对新辅助化学放疗的肿瘤反应:手术发病率的预测因子?

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

BACKGROUND: Increasing the rate of pathological complete remissions after neoadjuvant chemoradiation of rectal cancer has become a strategy to further improve the long-term oncological outcome of patients. This report evaluates the influence of preoperative intensified radiochemotherapy on the rate and outcome of surgical complications. MATERIALS AND METHODS: Patients with primary rectal cancer at stages cT3/4cNx or N+ without metastasis were preoperatively treated either with capecitabine and irinotecan or with capecitabine, irinotecan and ceutximab with a concurrent radiation (50.4 Gy). Surgery was scheduled 4-7 weeks after completion of the chemoradiation. Perioperative complications were prospectively documented during the patient's hospital stay. RESULTS: Fifty-nine patients (median age 60; male/female: 46/13) undergoing surgery at a single center were analysed. The median distance of the tumour from the dentate line was 5 cm. The operations performed were low anterior resection (n=45), Hartmann'sprocedure (n=4) and abdominoperineal resection (n=10). Total mesorectal excision with R0-resection was accomplished in all but one patients. Histopathological regression was described in four grades (0-3) as defined by the Japanese Society for Cancer of the Colon and Rectum. Tumors were called major responsive when assigned to the regression grades 3 or 2, and minor or nonresponsive at regression grades 1 or 0. In total, 33 patients (55.9%) had a regression grade 2 or 3. Among them, 12 patients showed a pathological complete response without any residual cancer cell (20.3%). Seven out of 45 patients (15.5%) with sphincter-preserving surgery suffered from suture breakdown; they all had previously shown a major response of the resected tumor. Two of them died during the hospital stay. CONCLUSIONS: While in general, patients undergoing neoadjuvant intensified treatment suffer from a slight increase in surgical complications, this is markedly enhanced in patients with good treatment responses. Our results underline the oncological benefit of intensified neoadjuvant chemoradiation, but the severity of complications in low rectal anastomosis of patients with good response after neoadjuvant therapy should alert surgeons and oncologists.
机译:背景:提高直肠癌新辅助化学放疗后病理完全缓解的比率已成为进一步改善患者长期肿瘤学结局的策略。该报告评估了术前强化放化疗对手术并发症发生率和预后的影响。材料与方法:术前用卡培他滨和伊立替康或卡培他滨,伊立替康和西妥昔单抗同时放疗(50.4 Gy),对患有cT3 / 4cNx或N +期无转移的原发性直肠癌患者进行术前治疗。化学放疗完成后的4-7周安排了手术时间。前瞻性地记录了患者住院期间的围手术期并发症。结果:分析了在单个中心接受手术的59例患者(中位年龄为60岁;男性/女性:46/13)。肿瘤距齿状线的中位距离为5 cm。所进行的手术是低位前切除术(n = 45),Hartmann手术(n = 4)和腹部手术切除术(n = 10)。除一名患者外,其余所有患者均进行了R0切除的全直肠系膜切除。根据日本结肠癌和直肠癌学会的定义,组织病理学退化分为四个等级(0-3)。当将肿瘤归为回归等级3或2时,将其称为主要反应,将回归等级1或0归为轻度或无反应。总共有33例患者(55.9%)的回归等级为2或3。其中,有12例患者表现为病理完全反应,无残留癌细胞(20.3%)。 45例保留括约肌的患者中有7例(15.5%)缝合破裂;他们以前都显示了切除肿瘤的主要反应。其中两人在住院期间死亡。结论:一般而言,接受新辅助强化治疗的患者的手术并发症略有增加,而对治疗反应良好的患者的并发症明显增加。我们的结果强调了加强新辅助化学放疗的肿瘤学益处,但新辅助治疗后反应良好的患者低位直肠吻合术的并发症严重程度应提醒外科医师和肿瘤学家。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号